Anne Lynn S. Chang - Concepedia

Author

Anne Lynn S. Chang

Also Known As

A Chang, A S Chang, A. Chang, A. L. S. Chang, A. S. Chang, A. X. Chang, A.L. Chang, A.L. S Chang, A.L.S. Chang, A.S. Chang

454

Publications

32K

Citations

H-Index

161

Concepts

All Affiliations

Stanford University The University of Texas MD Anderson Cancer Center University of Colorado Denver Regeneron (United States)Royal North Shore Hospital

About

Anne Lynn S. Chang is an author at Stanford University specializing in medicine, dermatology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	45	6.2K
2	Health Sciences	9	9	838
3	Engineering	5	5	461
4	Language Studies	5	5	424
5	Natural Sciences	2	2	118

Anne Lynn S. Chang

102

Publications

13.7K

Citations

H-Index

Page 1

	Year	Citations
Clonal replacement of tumor-specific T cells following PD-1 blockade Kathryn E. Yost, Ansuman T. Satpathy, Daniel K. Wells, Nature Medicine Tumor ImmunologyCancer ImmunosurveillanceMedicineImmunologyTumor Immunity	2019	1.5K
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro, New England Journal of Medicine	2012	1.4K
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, New England Journal of Medicine	2018	1.3K
Massively parallel single-cell chromatin landscapes of human immune cell development and intratumoral T cell exhaustion Ansuman T. Satpathy, Jeffrey M. Granja, Kathryn E. Yost, Nature Biotechnology ChromatinSystems BiologyLymphocyte DevelopmentImmune Cell DevelopmentMedicine	2019	1K
Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang, The Lancet Oncology Single-arm TrialMedicinePathologyDermatologyPhase 2	2020	457
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial Michael R. Migden, Alexander Guminski, Ralf Gutzmer, The Lancet Oncology Surgical OncologyMedicineMetronomic TherapyDermatologyCancer Treatment	2015	419
Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma Scott X. Atwood, Kavita Y. Sarin, Ramon J. Whitson, Cancer Cell OncologyHealth SciencesSomatic VariantTumor HeterogeneityMedicine	2015	415
SUTime: A library for recognizing and normalizing time expressions Anne Lynn S. Chang, Christopher D. Manning	2012	378
Stanfordâ€™s Multi-Pass Sieve Coreference Resolution System at the CoNLL-2011 Shared Task Heeyoung Lee, Yves Peirsman, Anne Lynn S. Chang, Conference on Computational Natural Language Learning EngineeringEntity SummarizationConll-2011 Shared TaskSemanticsText Mining	2011	347
Heterogeneity in old fibroblasts is linked to variability in reprogramming and wound healing Salah Mahmoudi, Elena Mancini, Lucy Xu, Nature Regenerative MedicineOld FibroblastsFibrosisWound CareWound Healing	2019	292

Page 1